亚虹医药：APL-2401 临床试验申请获国家药品监督管理局批准

Core Viewpoint - The company Aihong Pharmaceutical (688176.SH) has received approval from the National Medical Products Administration (NMPA) for its clinical trial application of APL-2401 (ASN-8639 tablets) in patients with advanced solid tumors driven by FGFR2/3 [1] Group 1 - APL-2401 is a first-class innovative drug developed globally in parallel [1] - The clinical trial design and submission materials meet international clinical trial technical standards [1] - The project was approved under the "30-day channel" established by the NMPA's announcement on optimizing the review and approval of innovative drug clinical trials, and it received approval in just 22 working days [1]